Search company, investor...

Sloning BioTechnology

sloning.de

Founded Year

2000

Stage

Acquired | Acquired

Valuation

$0000 

About Sloning BioTechnology

The company offer high quality, tailored protein engineering solutions to the company's industrial and biopharmaceutical customers worldwide.The company's core technology is Slonomics, a DNA engineering platform using defined sets of double stranded DNA tripaims to let.

Headquarters Location

Zeppelinstrasse 4

82178,

Germany

Missing: Sloning BioTechnology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sloning BioTechnology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Sloning BioTechnology Patents

Sloning BioTechnology has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/22/2002

5/1/2018

Grant

Application Date

11/22/2002

Grant Date

5/1/2018

Title

Related Topics

Status

Grant

Latest Sloning BioTechnology News

Sloning BioTechnology GmbH Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 1, 2016

Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Sloning BioTechnology GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sloning BioTechnology GmbH Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Sloning BioTechnology GmbH since January 2007. Key Findings Provides intelligence on Sloning BioTechnology GmbH MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Sloning BioTechnology GmbH and its subsidiaries since 2007. Information about key financial and legal advisors for Sloning BioTechnology GmbH's financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Sloning BioTechnology GmbH's growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Sloning BioTechnology Frequently Asked Questions (FAQ)

  • When was Sloning BioTechnology founded?

    Sloning BioTechnology was founded in 2000.

  • What is Sloning BioTechnology's latest funding round?

    Sloning BioTechnology's latest funding round is Acquired.

  • Who are the investors of Sloning BioTechnology?

    Investors of Sloning BioTechnology include MorphoSys, DEWB, KfW, 3i Group, HBM Healthcare Investments and 3 more.

  • Who are Sloning BioTechnology's competitors?

    Competitors of Sloning BioTechnology include c-LEcta, LungLife AI, PhaseBio Pharmaceuticals, CMC Biologics, Catalyst Biosciences and 11 more.

Compare Sloning BioTechnology to Competitors

A
Athena Environmental Sciences

AthenaES specializes in the development and commercialization of advanced biotechnology-based products. Throughout its eleven year history, the company has maintained a broad perspective for applying its core competency, the use of proteins and enzymes for commercial applications, to develop products. As such, the company currently markets its products and services through two business units and maintains an exploratory R&D group. The Athena Enzyme Systems Group aims to provide specialty reagents and proteins for the production and recovery of recombinant proteins along with providing contract R&D services. Products include: Expression Media, Serum-free Media, Protein Refolding kits, and the PDQ Protease Assay. This business unit also aims to provide specialized contract research, development and manufacturing services for the production of recombinant proteins. The Athena Environmental Services Group designs, develops and manufactures environmentally responsible products. Products developed include: The Bilge Pill, a biodegradable cleaning product for the removal of oil in boat bilges, and a plant nutrient supplement used in hydroponics, hobby gardens and horticulture that replaces conventional fertilizers, and the Sting Thing, an enzyme-based invertebrate sting treatment product. More recently, this group developed and has introduced a water-soluble, reversible glue, MagiGlue. The Athena Exploratory Science Group has the mission to pursue research with the potential for commercial, environmental and social impact. These projects are far reaching in their scope and represent high risk, high-value projects.

L
Laureate Pharma

Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.

I
Informed Medical Communications

Informed Medical is an interactive medical information services provider that enables biopharmaceutical companies to market directly to physicians and patients.

R
Recoly

Recoly N.V., a Netherlands Antilles based biotechnology company, is in the business of developing or acquiring platform technologies for use in the health care industry. Through the efforts of its research and development team, Recoly has developed a patented, platform technology which has been shown to prolong the half-life and improve the biological efficacy of protein and peptide pharmaceuticals by formulating them with PEGylated liposomes. The proteins and peptides bind non-covalently and yet with high affinity to the external surface of the liposomes; the proteins and peptides maintain their biological activity. No change in the protein/peptide manufacturing process is required. Recoly's business model is to partner with pharmaceutical and biotechnology companies to develop improvements of approved pharmaceutical products and thereby extend product franchises and enlarge product pipelines.

C
Celgen Biopharmaceuticals

Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.

Bird Rock Bio Logo
Bird Rock Bio

Bird Rock Bio, formerly RuiYi, is a clinical stage biopharmaceutical company focused on developing immuno-inflammatory regulators. The company's strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best in class therapeutic antibodies with significant clinical and commercial differentiation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.